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Histone deacetylase (HDAC) enzymes posttranslationally modify lysines on histone and nonhistone proteins and play crucial
roles in epigenetic regulation and other important cellular processes. HDAC inhibitors (e.g., suberoylanilide hydroxamic acid
[SAHA; also known as vorinostat]) are used clinically to treat some cancers and are under investigation for use against many
other diseases. Development of newHDAC inhibitors for noncancer indications has the potential to be accelerated by piggy-
backing onto cancer studies, as several HDAC inhibitors have undergone or are undergoing clinical trials. One such compound,
SB939, is a new orally active hydroxamate-based HDAC inhibitor with an improved pharmacokinetic profile compared to that of
SAHA. In this study, the in vitro and in vivo antiplasmodial activities of SB939 were investigated. SB939 was found to be a potent
inhibitor of the growth of Plasmodium falciparum asexual-stage parasites in vitro (50% inhibitory concentration [IC50], 100 to
200 nM), causing hyperacetylation of parasite histone and nonhistone proteins. In combination with the aspartic protease inhib-
itor lopinavir, SB939 displayed additive activity. SB939 also potently inhibited the in vitro growth of exoerythrocytic-stage Plas-
modium parasites in liver cells (IC50,150 nM), suggesting that inhibitor targeting to multiple malaria parasite life cycle stages
may be possible. In an experimental in vivomurine model of cerebral malaria, orally administered SB939 significantly inhibited
P. berghei ANKA parasite growth, preventing development of cerebral malaria-like symptoms. These results identify SB939 as a
potent new antimalarial HDAC inhibitor and underscore the potential of investigating next-generation anticancer HDAC inhib-
itors as prospective new drug leads for treatment of malaria.
Widespread resistance of Plasmodium parasites to commonlyavailable antimalarial drugs (23) and the lack of a licensed
vaccine have necessitated increased efforts in the discovery and
development of new antimalarial agents. Of particular interest are
new antimalarial drug candidates which act on novel parasite tar-
gets or mechanisms associated with parasite survival or develop-
ment. Transcriptional control inmalaria parasites is complex, and
regulatory mechanisms are the subject of intense investigation.
Nevertheless, there is increasing evidence that targeting of tran-
scriptional regulation represents a potential new therapeutic ap-
proach for malaria. Histone deacetylase (HDAC) enzymes, which
are key regulators of transcription and validated therapeutic tar-
gets for some types of cancer, are promising new antimalarial drug
targets (7).
Histone acetyltransferases (HATs) posttranslationally modify
proteins by catalyzing the transfer of an acetyl group from acetyl-
coenzyme A (acetyl-CoA) to the ε-nitrogen on the side chain of
lysines, whileHDACs catalyze the reverse reaction. These enzymes
play crucial roles in modulating the acetylation state of histone
proteins, contributing to alterations in chromatin structure and
transcription (17). Many nonhistone proteins have also been
identified as HDAC substrates (15, 22, 30). As a result, protein
lysine acetylation is now considered common and is thought to
play critical roles in regulatingmany important cellular processes,
including protein stability, protein-protein interactions, protein
localization, and DNA-binding properties of proteins (44).
Mammalian HDACs are classified into four classes (29, 31).
Class I, II, and IV HDACs share a zinc cofactor catalytic core (27,
59), while class III HDACs use NAD to deacetylate their sub-
strates. Five HDAC-encoding genes have been identified in the
Plasmodium falciparum genome: one encoding a homologue of
class I HDACs (PfHDAC1), two encoding homologues of class II
HDACs (PfHDAC2 and -3), and two encoding class III HDAC
homologues (PfSir2A and PfSir2B) (25, 28, 36, 61). PfSir2A and
PfSir2B are not essential for asexual, blood-stage growth of P.
falciparum in vitro. However, both play roles in regulating the
expression of subsets of P. falciparum virulence genes, indicating
potentially important roles in immune evasion in vivo (25, 28, 61).
Although the functional roles of the class I and II PfHDAC homo-
logues have not yet been elucidated, PfHDAC1 is a likely target of
antimalarial HDAC inhibitors such as suberoylanilide hy-
droxamic acid (SAHA) (50).
In eukaryotic cells, interfering with HDAC action by using
small-molecule inhibitors results in an accumulation of acetylated
histones, alterations to transcription, and various cellular re-
sponses, such as apoptosis, differentiation, and changes in cell
cycle progression. ThreeHDAC inhibitors are currently in clinical
use for treatment of cancer, including two hydroxamate-based
compounds (SAHA [Zolinza; Merck & Co.] and 4SC-201
[resminostat; also known as 4SC]) and a cyclic depsipeptide
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(FK228 [romidepsin; Gloucester Pharmaceuticals Inc.]). In addi-
tion, several HDAC inhibitors are now undergoing clinical trials
(40, 42, 63). A number of HDAC inhibitors, particularly hydrox-
amates, are also potent (50% inhibitory concentrations [IC50s] of
200 nM) and selective (selectivity indexes of100) inhibitors of
P. falciparum parasites in vitro (reviewed in references 5 and 7).
Some, including SAHA, also have good ex vivo activity (IC50s of
200 to 500 nM) against field isolates of P. falciparum and P.
vivax, the second most important human-infecting malaria para-
site (41). Limited data are available on HDAC inhibitor action in
vivo in mouse malaria models, but one cyclic tetrapeptide (apici-
din) and two hydroxamate compounds (suberic bishydroxamate
[SBHA] andWR301801) have shown promising inhibitory activ-
ity profiles (1, 8, 21, 24). This validates further studies on next-
generation HDAC inhibitors for treatment of malaria, especially
novel versions with improved pharmacokinetic profiles. The ex-
tensive research being undertaken to develop HDAC inhibitors
for treating human cancers provides a unique opportunity to
piggyback onto these studies for noncancer indications such as
malaria.
In this study, we tested the in vitro and in vivo antiplasmodial
efficacies of a new, orally bioavailable, hydroxamate-basedHDAC
inhibitor undergoing clinical trials for cancer (35, 47, 52, 65, 67).
SB939 (pracinostat; S*BIO), a pan-HDAC inhibitor acting on
class I, II, and IVHDACs (47, 65), has a longer in vivo half-life (t1/2
of 2.4 h) than those of other hydroxamate-based HDAC inhibi-
tors, such as SAHA (t1/2 of 0.75 h) (Table 1). Here we present data
on the first reported noncancer application of this compound.We
show that SB939 is a potent inhibitor of the in vitro growth of
asexual P. falciparum parasites in human erythrocytes and of P.
berghei exoerythrocytic-stage parasites in human hepatocytes.
SB939 hyperacetylates P. falciparum histone and nonhistone pro-
teins, demonstrating its mode of action as an HDAC inhibitor in
P. falciparum. In vitro combination studies demonstrated an ad-
ditive interaction with the antimalarial aspartic protease inhibitor
lopinavir. In vivo, orally administered SB939 significantly inhib-
ited parasite growth in a mouse model of infection, protecting
against experimental cerebral malaria (ECM)-like symptoms.
MATERIALS AND METHODS
Compounds. SAHA (Sigma) and (E)-3-{2-butyl-1-[2-(diethylamino)
ethyl]benzimidazol-5-yl}prop-2-ene hydroxamic acid (SB939; Selleck
Chemicals) were prepared as 10 mM stock solutions in 100% dimethyl
sulfoxide (DMSO) for in vitro assays and in 50%DMSO–50%phosphate-
buffered saline (PBS) immediately prior to use for in vivomouse malaria
studies. Chloroquine (chloroquine diphosphate salt; Sigma)was prepared
in Milli-Q ultrapure water for in vitro and in vivo studies.
Culture of P. falciparum parasites. P. falciparum 3D7 and Dd2 par-
asites were cultured in O human erythrocytes in RPMI 1640 medium
(Life Technologies) supplemented with 10% heat-inactivated human se-
rum and 50 mg/liter hypoxanthine as previously described (6).
P. falciparum growth inhibition assays. Assessment of antimalarial
activity against P. falciparum was carried out with a 72-h isotopic mi-
crotest as previously described (6, 24), using synchronous ring-stage-in-
fected erythrocytes (0.5% parasitemia and 2.5% hematocrit). [3H]hypox-
anthine incorporationwas determined by harvesting cells ontoMicroBeta
1450 filter mats (Wallac) and counting using a MicroBeta 1450 liquid
scintillation counter. The percent inhibition of growth compared to that
of matched DMSO (0.5%) controls was determined for at least three in-
dependent experiments, each carried out in triplicate. IC50s were calcu-
lated using linear interpolation of inhibition curves (33). A nonparamet-
ric two-tailed t test (Mann-Whitney) was used for statistical analysis.
Isobolograms. Antimalarial drug combinations were assessed by
isobologram analysis as previously described (58). All assays were per-
formed in 96-well microtiter plates. Each well contained 100 l of cell
culture and 100 l of each drug dilution or control. Plates were then
labeled with [3H]hypoxanthine (0.5 Ci/well; Perkin Elmer). After 48 h,
cells were harvested on MicroBeta 1450 filter mats (Wallac) and counted
using a MicroBeta 1450 liquid scintillation counter. Three independent
experiments were performed. Isobolograms were constructed using data
from all experiments. Briefly, concentrations of each drug that alone or in
combination resulted in 50% growth inhibition were plotted as fractional
inhibitory concentrations (18). Using the SAAM II program (SAAM In-
stitute, Seattle, WA), the following standard hyperbolic function (12) was
fitted to the data: Yi 1 {XI/[XI e
I (1Xi)]}, where Yi is the IC50
of drug A combined with drug B, Xi is the IC50 of drug B combined with
drug A, and I is the interaction value. Positive values for I indicate syner-
gism, and negative values indicate antagonism; addition occurs when I is
zero. The significance of the difference of I from zero (P values of0.01
indicate an additive interaction) was assessed using Student’s t test.
Mammalian cytotoxicity assays. Human umbilical vein endothelial
cells (HUVEC), proximal tubule epithelial cells (PTC), and neonatal fore-
skin fibroblast (NFF) cells were cultured in RPMImedium (Life Technol-
ogies) supplementedwith 10%heat-inactivated fetal calf serum (CSLBio-
sciences) and 1% streptomycin (Life Technologies). Five thousand cells
were seeded into wells of a 96-well tissue culture plate and cultured for 24
h at 37°C and 5% CO2. Following adhesion, HUVEC and PTC were
starved in serum-free RPMImedium for a further 24 h. All three cell lines
were treated with SB939, SAHA, and chloroquine in a 3-fold dilution
series beginning at 100 M. After 72 to 96 h, medium was removed
from each, and 50 l of staining solution was added, i.e., MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; 1 mg/ml) for
HUVECandPTCandsulfo-rhodamineB(0.4%)(Sigma) forNFFcells.After
staining for 1h, 100l isopropanolwas added andplateswere read at 570nm
in an enzyme-linked immunosorbent assay (ELISA)microplate reader.
Liver-stage assays. P. berghei ANKA sporozoites dissected from the
salivary glands of Anopheles stephensimosquitoes were applied to HepG2
cells grown on coverslips (56). The medium was exchanged for fresh me-
dium containing the test compound or the control antimalarial drug pri-
maquine after 1 h and then replaced again at 24 and 48 h. Infected cells
were incubated at 37°C and 8% CO2 for 53 h, fixed in 4% paraformalde-
hyde-PBS for 20 min, permeabilized using cold methanol, and labeled
with a 1:200 dilution ofmouse polyclonal antibody raised against wholeP.
berghei (46) and a 1:200 dilution of anti-P. falciparum ACP antibody (64)
in 3% bovine serum albumin (BSA) for 1 h, followed by secondary label-
ing with Alexa Fluor antibodies. Nuclei were stained with DAPI (4=,6-
diamidino-2-phenylindole). Parasites were imaged and counted using a
Leica confocalmicroscope. Results are for three independent experiments
and give the percent inhibition of growth compared to that of matched
vehicle (0.01% DMSO)-treated parasites. IC50s were determined using
the four-parameter model (Sigmaplot).
PfHDAC1 homology model and ligand docking. The PfHADC1
amino acid sequence (http://www.uniprot.org; accession number
Q7K6A1) was used in a BLAST (2) search of the Protein Data Bank (PDB)
(14) to identify crystal structures of proteins with similar sequences, giv-
ing human HDAC2 (PDB accession no. 3max; resolution of 2.05 Å; 63%
identity) (16) and HDAC8 (PDB accession no. 1t64; resolution of 1.90 Å;
41% identity). These template structures and PfHDAC1 sequences were
aligned using ClustalW (60) and manually optimized by removing the
N-terminal loop 1 of HDAC8 and PfHDAC1 loop 2. Residues Gly93 to
Thr96 were not templated to either structure. Modeller (53) was used to
build 15 all-atomhomologymodels of PfHDAC1, including the active site
Zn atom and the ligand trichostatin A (TSA). The homology model with
the lowest DOPE score (57) was selected and structurally assessed via a
Ramachandran plot (91% in favored regions) and via Verify_3D (95% of
residues scored 0.2) (26). Sybyl-X 1.3 (Tripos International, St. Louis,
MO) was used to superimpose crystal structures with the PfHDAC1 ho-
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mology model; minor side chain geometries and protonation states near
the active site Zn atom were corrected manually. This homology model
was then used in GOLD for ligand docking studies.
The ligands SB939, TSA, and SAHA were built in Sybyl-X 1.3 and
minimized using the MFF94s force field (MMFF94 charges; dielectric
constant of 80; distance dependent) to a terminal gradient of 0.05 kcal/
mol-A. GOLD was then used to perform 15 dockings of the ligands in the
homology model, using the zinc-bound hydroxamate group of TSA
(CONHOH atoms) as a scaffold constraint (10 kcal/mol). Side chains of
Thr96, Asp97, Ser146, Arg268, and Leu269 were allowed to rotate freely dur-
ing the docking experiment, and conformations were scored using Gold-
score and rescored using Chemscore (48).
Protein hyperacetylation assays. Protein hyperacetylation assays
were carried out by incubating synchronous trophozoite-stage P. falcipa-
rum 3D7 parasites (3 to 5% parasitemia; 5% hematocrit) in six-well tissue
culture plates for 3 h under standard in vitro culture conditions with
different concentrations of compound or vehicle (0.05% DMSO). In-
fected erythrocytes were lysed with 0.15% saponin (Sigma), and parasite
pellets were obtained by centrifugation. Pellets were washed extensively in
cold PBS, pH 7.4, to remove hemoglobin and then resuspended in SDS-
PAGE loading dye, heat denatured at 96°C for 3 min, and separated via
SDS-PAGE. Proteins were transferred to polyvinylidene difluoride
(PVDF)membranes (Roche), andWestern blotting was carried out using
Odyssey blocking buffer (Li-Cor Biosciences) according to the manufac-
turer’s instructions. Anti-(tetra)acetyl H4 histone primary antibody (Mil-
lipore) was used with goat anti-rabbit–infrared (IR) dye secondary anti-
body (Li-Cor Biosciences) to detect changes in histone H4 acetylation.
Anti-pan-acetyl (K103) monoclonal antibody (Cell Signaling Technol-
ogy) was used with goat anti-rabbit–IR dye secondary antiserum (Li-Cor
Biosciences) to detect changes in nonhistone protein acetylation. Mem-
branes were imaged using an Odyssey infrared imaging system (Li-Cor
Biosciences).
In vivo antimalarial efficacy studies. The in vivo antimalarial efficacy
of compounds was examined in an ECM model using P. berghei ANKA
parasites constitutively expressing a luciferase reporter gene (termed P.
berghei ANKAluc) (3). Groups of five C57BL/6j mice were infected via
intraperitoneal (i.p.) injection with 105 P. berghei ANKAluc-infected
erythrocytes from an infected passage mouse. Two hours later, mice were
treated with 100 l of test compound or vehicle control (50% DMSO in
PBS) via oral gavage. Mice were treated with compound or vehicle for a
total of 3 days, either as a single dose or as a split dose (twice daily [BID]),
with a 4-h interval between doses. A single daily dose of chloroquine (10
mg/kg of body weight in PBS) for 3 days, beginning at 2 h postinfection
(p.i.), was used as a positive control. Peripheral parasitemia was moni-
tored daily from day 4 p.i. bymicroscopic examination of Giemsa-stained
thin blood smears prepared from tail bleeds. Parasite burden as ameasure
of bioluminescence (total flux; photons [p]/s) was measured from day 4
p.i. by anesthetizing mice with isoflurane (Bomac, New Zealand), inject-
ing them with 100 l luciferin (5 mg/ml in PBS; Caliper Life Sciences)
substrate i.p., and then, after 4 min, imaging them using a Xenogen IVIS
100 imaging system (Caliper Life Sciences). Mice were housed in a venti-
lated cabinet (light from 8 p.m. to 8 a.m. and dark from 8 a.m. to 8 p.m.;
Iffa Credo). All animal work was carried out according to protocols under
the Animal Code of Practice and approved by the QIMR Animal Ethics
Committee following guidelines mandated by the National Health and
Medical Research Council of Australia.
RESULTS
In vitro activity of SB939 against P. falciparum asexual-stage
parasites andmammalian cells. In vitro inhibition studies against
asexual-stage P. falciparum parasites growing in human erythro-
cytes showed that SB939 had potent activity (IC50s of100 to 200
nM) against chloroquine-sensitive (3D7) and chloroquine-resis-
tant (Dd2) P. falciparum parasites (Table 2). The IC50s of a refer-
ence HDAC inhibitor (SAHA) and the antimalarial drug chloro-
quine were similar to those previously reported (Table 2) (8, 24).
The activity of SB939 against P. falciparum versus normal mam-
malian cell growth was assessed using HUVEC, PTC, and NFF
cells (Table 2). These data were compared to previously published
cytotoxicity data for normal human dermal fibroblast (NHDF)
cells (47). Although low toxicity was reported against NHDF cells
(IC50 of100 M) (47), SB939 had a greater inhibitory potency
on the cells examined in this study, with IC50s ranging from 0.8 to
3.2 M (Table 2).
In vitro combination studies of SB939with primaquine, pip-
eraquine, and lopinavir. Isobolograms describing the interac-
tions of SB939 with primaquine and piperaquine against the chlo-
roquine-sensitive P. falciparum line 3D7 demonstrated that the
antiplasmodial activities of these compound combinations were
antagonistic (see Fig. S1 in the supplemental material), with I val-
ues of5 and1.4, respectively. However, SB939 and the pro-
tease inhibitor lopinavir behaved additively when combined (see
Fig. S1).
In vitro activity of SB939 against P. berghei exoerythrocytic-
stage parasites. The activities of SB939 and the control HDAC
TABLE 1 Structures and properties of different HDAC inhibitors
Compound Structure Mol wt clogP Cmax (M) F% t1/2 (h)
TSAa 302 1.9 132 ND 0.1
SAHAb 264 1.0 1.8 8 0.75
SB939b 358 3.2 6.1 34 2.44
a Cmax and t1/2 were determined for female BALB/c mice (n 3) after a single intraperitoneal dose of 80 mg/kg (54).
b Cmax, F%, and t1/2 were tested in female nude BALB/c mice (n 3) after a single oral dose of 50 mg/kg (47, 65).
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inhibitor SAHA against the exoerythrocytic stage of the parasite
life cycle were assayed using P. berghei ANKA sporozoites in cul-
tured HepG2 cells. Following a 1-h invasion period, cells were
cultured for 53 h in the presence of inhibitors and scored for
successful parasite development. SB939 and SAHA displayed sim-
ilar inhibitory profiles, with IC50s of 155.2 nM (	20.2 nM) and
164.8 nM (	18.3 nM), respectively (Fig. 1). At the concentrations
examined (up to 1M), neither compound caused any toxicity to
HepG2 cells compared to cells treated with vehicle (0.01%
DMSO) or grown in normal medium (not shown). The antima-
larial compound primaquine was used as a control and gave an
IC50 of 3.48 M (	0.42 M) against exoerythrocytic-stage para-
sites, similar to the previously published IC50 of this compound
(3.8 M), which is less active than its metabolites (11).
In silico docking studies. Binding of SB939 to an updated
homology structure model of PfHDAC1 was also examined.
This new PfHDAC1 homology model was generated withMod-
eller, using human HDAC8 and HDAC2 crystal structures and
improving the loop 1 and loop 2 regions (an amino acid align-
ment is shown in Fig. S2 in the supplemental material). GOLD
was used to dock TSA, SAHA, and SB939 (see Table 1 for struc-
tures) into the active site of PfHDAC1, using a hydroxamic acid
scaffold constraint. Cross docking TSA back into PfHDAC1
resulted in the top-ranked conformation, with a heavy-atom
root mean square deviation (RMSD) of 0.90 Å relative to the
original TSA conformation (values of 2 Å are considered
acceptable) (34). The top-ranked SAHA conformation docked
with the phenyl head group docked into the pocket between
loop 1 and loop 2 in a manner similar to that for the head group
of TSA (59). SB939 docked into PfHDAC1 with the indole
linker positioned between tunnel residues Phe148 and Phe203
and is shown in Fig. S3 in the supplemental material, with
potential H bonds indicated. The SB939 hydroxamic acid car-
bonyl oxygen makes a putative interaction with Tyr301-OH,
while the -NH group of the protonated and positively charged
nitrogen of SB939 makes a potential interaction with Asp98.
The linear butyl alkyl chain of SB939 was fitted into a surface
pocket between loop 1 and loop 2 (see Fig. S3).
SB939’s mode of action against P. falciparum asexual-stage
parasites. To assess the effect of SB939 on P. falciparum protein
acetylation, 3D7 trophozoite-stage parasites were treated for 3 h
with SB939, SAHA, or the antimalarial drug chloroquine, and
Western blotting was conducted. Compared to vehicle and chlo-
roquine control samples, SAHA and SB939 treatment resulted in
hyperacetylation of proteins of 12 to 15 kDa, as viewed using
antiserum specific for tetra-acetylated histone H4 (6) (Fig. 2). An
increased signal was also observed for an80- to 90-kDa protein
in HDAC inhibitor-treated samples, using a commercial antise-
rum that recognizes acetylated lysine residues (pan-reactive).
These data indicate that SB939 hyperacetylates both histone and
nonhistone proteins.
In vivo efficacy of oral SB939 in an experimental cerebral
malaria model. The in vivo efficacy of SB939 was examined in a
murine ECM model using C57BL/6J mice and P. berghei ANKA
parasites constitutively expressing a luciferase bioluminescence
TABLE 2 In vitro antimalarial activity of SB939
Compound
P. falciparum IC50 (M) Mammalian cell IC50 (M)
a
Selectivity indexb3D7 Dd2 NHDF cells HUVEC PTC NFF cells
SAHA 0.12	 0.04 0.19	 0.01 2.0	 0.04 1.8	 0.2 3.0	 0.5 4.90	 1.24 9–49
SB939 0.08	 0.03 0.15	 0.03 100 0.8	 0.1 3.2	 0.5 1.48	 0.61 4–1,250
Chloroquine 0.03	 0.09 0.15	 0.04 900 ND ND 39.53	 1.32 258–30,000
a SAHA cytotoxicity was previously tested against NHDF cells (20); SB939 cytotoxicity was previously tested against NHDF cells (47); SB939 and SAHA cytotoxicity was tested in
this study against HUVEC, PTC, and NFF cells; and chloroquine cytotoxicity was tested in this study against NFF cells and in previous studies against NHDF cells (55). ND, not
determined.
b Mammalian cell IC50/P. falciparum IC50. Larger values indicate greater parasite selectivity.
FIG 1 Inhibition of P. berghei exoerythrocytic-stage parasites. Dose-response
curves are shown for exoerythrocytic-stage P. berghei parasites treated with
HDAC inhibitors SAHA and SB939. Cells were treated with compounds for 53
h following invasion, fixed, stained, and scored by microscopy for successful
development of parasites within HepG2 cells. The percent parasite growth
compared to vehicle-only control parasite growth (mean	 standard error of
the mean [SEM]) is shown.
FIG2 Hyperacetylation of P. falciparum proteins by SB939. Synchronous 3D7
trophozoite-stage P. falciparum parasites were treated with 50 or 500 nM chlo-
roquine (CQ), SAHA, or SB939 or with vehicle only (control; 0.05% DMSO)
for 3 h. Following saponin lysis, parasite protein lysates were prepared and
SDS-PAGE andWestern blotting carried out using anti-acetyl H4 or anti-pan-
acetyl lysine (K103) antibodies. Coomassie blue staining was carried out as a
loading control.
Sumanadasa et al.
3852 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 N
ovem
ber 4, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
reporter protein. Oral administration of 25 mg/kg SB939 twice a
day for 3 days resulted in a significant reduction in peripheral
blood parasitemia (P  0.05 for days 3 to 7 p.i.) and parasite
biomass (P  0.05 for days 3, 4, 6, and 7) compared to those of
control mice (Fig. 3). Mice treated with the antimalarial drug
chloroquine (10 mg/kg; single oral dose daily for 3 days) had sub-
patent peripheral blood parasitemias until day 8 to 9 days p.i. (e.g.,
parasitemias on day 9 p.i. ranged from 0 to 3.1% [mean para-
sitemia of 1.0%]), an effect previously reported with this treat-
ment regimen. As expected, mice in the control group developed
ECM-like symptoms on day 6 or 7 p.i. and were euthanized. None
of the mice in the chloroquine- or SB939-treated groups had de-
veloped ECM-like symptoms by day 9 p.i., when the experiment
was ended.
Since cures were not achieved in mice treated with 2 doses of
25-mg/kg SB939 per day, the maximum reported tolerated daily
dose of this compound (100 mg/kg) in mice (47, 65) was exam-
ined.Mice were treated orally with 50mg/kg SB939 twice a day for
three consecutive days to achieve a total daily dose of 100 mg/kg.
Significant reductions in peripheral parasitemia and parasite bur-
den were observed for SB939 versus the control group of mice on
days 4 to 7 (P 0.05) (Fig. 4); however,micewere not cured at this
dose. Hyperparasitemias developed on days 12 to 16 p.i. in 4/5 mice
treated with SB939. Mice were euthanized when their parasitemias
reached30%.Onemousehadapeakperipheral parasitemiaonday
12 p.i. of12%, followedby a decrease in parasitemia (1.5%)until
day 22 p.i., when the experiment was ended. All mice in the control
group succumbed to ECM-like symptoms and were euthanized on
FIG 3 Effect of twice-daily treatment with 25 mg/kg SB939 on P. berghei ANKA-infected mice. Groups of five P. berghei ANKAluc-infected C57BL/6j mice were
treated orallywith 25mg/kg SAHA (dashed line) or vehicle only (50%DMSO inPBS) as a control (solid line) twice a day for 3 days, beginning at 2 h postinfection.
(A) Mean (	 SEM) peripheral blood parasitemia was determined by microscopic examination of Giemsa-stained thin blood smears. (B) Mean (	 SEM)
parasite-derived bioluminescence (flux) was determined using a Xenogen imager. Significant differences (*, P 0.05; **, P 0.01) in treated groups compared
to controls are indicated. (C) Images of mice on day 6 postinfection show increasing parasite-derived bioluminescence intensities from purple to red (a
luminescence scale is shown to the right).
FIG 4 Effect of twice-daily treatment with 50 mg/kg SB939 in mice infected with P. berghei ANKA. P. berghei ANKAluc-infected C57BL/6j mice (n  5) were
treated orally with 50 mg/kg SB939 (B and D) or vehicle only (50% DMSO in PBS) (A and C) twice a day for 3 days, beginning at 2 h postinfection. Peripheral
parasitemia (A and B) and parasite-derived bioluminescence (flux) (C and D) are shown for individual mice. Significant differences (*, P 0.05; **, P 0.01)
between the SB939 and control groups are indicated.
Antimalarial Activity of SB939
July 2012 Volume 56 Number 7 aac.asm.org 3853
 o
n
 N
ovem
ber 4, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
day 6 or 7.None of themice in the SB939 groupdevelopedECM-like
symptoms.
DISCUSSION
Antimalarial drug resistance is driving the search for new agents
able to either replace current drugs when they fail or complement
existing antimalarials as partner drugs in new combination ther-
apies. Here we investigated the antimalarial activity of a new hy-
droxamate-basedHDAC inhibitor that is currently in phase I clin-
ical trials for the treatment of cancer (52, 67). SB939 was
developed from a medicinal chemistry program focused on ad-
dressing the general lack of metabolic stability and poor in vivo
pharmacokinetics displayed by HDAC inhibitors (65). From a
medicinal chemistry point of view, SB939 obeys Lipinski’s rule of
five (39) and has the appropriate size, hydrophobicity, and polar
surface parameters (e.g., molecular weight  358, octanol-water
partition coefficient [clogP] 3.2, number of H-bond donors
2, number of H-bond acceptors 6, and total polar surface area
[TPSA] 68%) required for oral bioavailability. It is therefore not
surprising that SB939 has an improved pharmacokinetic profile
compared to that of SAHA, the first HDAC inhibitor to be ap-
proved for human use against cutaneous T cell lymphoma (Table
1). Preclinical pharmacokinetic studies in mice have shown that
orally administered SB939 (50 mg/kg; single dose) reaches a
highermaximum concentration (Cmax), with higher oral bioavail-
ability (F%) and a longer half-life (t1/2), than that of SAHA (Table
1). In vitro safety pharmacology data also show that SB939 (10
M) does not interfere with the activity of non-HDAC enzymes,
including other Zn2-dependent enzymes, G-protein-coupled re-
ceptors, monoamine transporters, and ion channels (47, 65).
SB939 thus has a promising profile as a new HDAC inhibitor.
This study is the first to report on noncancer activities of
SB939. We found SB939 to be a potent inhibitor of the in vitro
growth of P. falciparum malaria parasites, with the compound
being active against both chloroquine-sensitive (3D7) and -resis-
tant (Dd2) lines (Table 2). SB939 was less potent against Dd2 than
against 3D7 (P 0.05), suggesting that additional studies may be
required to determine if cross-resistance is a potential concern.
When the in vitro growth inhibition potency against P. falciparum
parasites was compared to that of mammalian cell lines, a wide
variation in selectivity indexes was observed. While SB939 was
1,000 times more active as an inhibitor against P. falciparum
growth than against NHDF cells (47), much lower (1- to 5-fold)
selectivity indexes were obtained for the other cell lines tested in
this study (Table 2). This differential killing selectivity may be due
to the different expression levels of the HDAC isoform(s) in dif-
ferent cell lines.
Malaria control and treatment currently rely on combination
therapy to try to counteract the development of antimalarial drug
resistance. As such, it is important that new antimalarial drugs be
evaluated as therapeutic options in concert with complementary
partner drugs.Only limited studies have examined the potential of
HDAC inhibitors as partner drugs against malaria parasites. An-
tagonist effects have been reported for the antimalarial hydroxam-
ate HDAC inhibitor WR301801 combined in vitro with meflo-
quine, chloroquine, artemisinin, or the antimicrobial agent
azithromycin (24). In this study, we tested two clinically used an-
timalarial drugs that have not yet been combined with HDAC
inhibitors, namely, piperaquine, which targets asexual-stage par-
asites, and primaquine, which is used primarily to target liver-
stage parasites but also has modest activity against asexual-stage
parasites (51, 62). We showed that SB939 antagonizes the anti-
plasmodial activity of both of these antimalarial drugs. We also
tested a clinically utilizedHIV protease inhibitor, lopinavir, that is
currently used to treat HIV in HIV-Plasmodium-coinfected indi-
viduals and that we have previously shown to have antimalarial
activity (4). We found that SB939 behaved in an additive fashion
with lopinavir. This is the first positive in vitro interaction to be
reported for an HDAC inhibitor and another antimalarial com-
pound against P. falciparum. While this finding needs to be inves-
tigated further in vivo, it may also have important implications for
the treatment of patients with malaria and HIV/AIDS, who may
concurrently be receiving antiretroviral protease inhibitors.
Moreover, given that recent data suggest that HIV protease inhib-
itor and HDAC inhibitor combination treatment regimens target
latent virus (38, 43), additional antimalarial benefits of this com-
bination may also be possible.
In this study, we conducted the first investigation of the in vitro
growth inhibition activity of HDAC inhibitors against exoeryth-
rocytic (liver)-stage Plasmodium parasites. Both SB939 and SAHA
potently inhibited the development of P. berghei ANKA mouse
malaria parasites within HepG2 liver cells. Although the target of
these compounds in liver-stage parasites is not yet known, SAHA
is known to inhibit recombinant PfHDAC1 activity (50), and the
gene encoding this protein is transcribed in P. falciparum liver-
stage parasites as well as in asexual- and gametocyte-stage para-
sites (9). Expression data for the P. berghei ANKA homologue
(PbHDAC1) of PfHDAC1 in liver-stage parasites are not yet avail-
able, but considering that the two proteins share 94% amino acid
identity (9), it is likely that HDAC inhibitors will target this pro-
tein in rodent malaria parasites. Our finding that HDAC inhibi-
tors can target multiple Plasmodium life cycle stages in vitro has
potentially important implications for the future development of
this class of compounds as antimalarial drugs. Although most an-
timalarial drugs in clinical use target intraerythrocytic, asexual-
stage parasites, very few are known to act on other life cycle stages,
such as exoerythrocytic liver-stage parasites or gametocytes, the
stage transmitted to the mosquito. Our data provide the first val-
idation of HDAC inhibitors as liver-stage drug leads. Findings
from this study suggest that SB939 acts as an HDAC inhibitor in
malaria parasites.
Our in silicodocking studies give an improved homology struc-
tural model of PfHDAC1 and also provide evidence for binding to
SB939, in a fashion similar to that of TSA and SAHA. We also
demonstrated that SB939 has the same mode of action as previ-
ously used antimalarial HDAC inhibitors (6, 21, 24), causing hy-
peracetylation of both histone and nonhistone proteins in P.
falciparum asexual-stage parasites. The nonhistone protein hyper-
acetylated by SB939 treatment was not identified in this study, but
its molecular mass (80 to 90 kDa) corresponds well to that of
heat shock protein 90 (PfHSP90), which was recently identified as
being hyperacetylated in TSA-treated P. falciparum parasites by
use of the same pan-acetyl lysine antiserum as that used in this
study (49). Interestingly, HSP90 is known to be a nonhistone tar-
get of HDAC action in mammalian cells (10, 37).
The in vivo efficacy of SB939 was examined using a murine
ECM model. Cerebral malaria (CM) pathogenesis is poorly un-
derstood; however, cerebral pathology is associated with mature
infected erythrocytes sequestering in the microvasculature of tis-
sues, including the brain (13, 66). This results in immune evasion
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by mature P. falciparum-infected erythrocytes, preventing re-
moval by the spleen and facilitating parasite survival (13). ECM
caused by P. berghei ANKA parasites in mice shares some features
with human CM, with susceptible mice developing neurological
symptoms such as paralysis, ataxia, convulsions, and coma. This
generally occurs 6 to 8 days after infection with P. berghei ANKA
parasites, results in 80 to 100% mortality, and is associated with
low peripheral blood parasitemia (3). Studies of ECM in mouse
models of malaria have been facilitated greatly by the recent ad-
vent of a transgenic, luciferase-expressing P. berghei ANKA line
that allows not onlymeasurement of peripheral blood parasitemia
but also measurement of parasite biomass in peripheral tissues
(3). Orally administered SB939 was found to be effective in reduc-
ing both peripheral parasitemia and total parasite burden at doses
of up to 100 mg/kg/day in the ECM model. Although mice were
not cured, SB939 treatment prevented the development of ECM-
like symptoms, and mice did not develop hyperparasitemia until
day 15 to 22 p.i. In contrast to the result obtained with twice-daily
dosing of SB939, when this compound was administered orally as
a single daily dose of 50 or 100 mg/kg, a significant reduction in
parasite biomass was observed on day 6 p.i., but there was no
difference on day 7 p.i. (see Fig. S4 in the supplemental material).
The poorer antiparasitic effect with a single dose of SB939 than
with a twice-daily dose is likely due to the in vivo half-life of SB939
(2.4 h) being insufficient to attenuate parasite growth.
HDAC inhibitors are a promising new class of antimalarial
compounds, with several compounds displaying potent in vitro
and ex vivo activity against P. falciparum and P. vivax parasites.
Recent studies on the effects of HDAC inhibitors on the growth
and development of P. falciparum have also provided new insights
into transcriptional regulation in malaria parasites (19, 32).
Alterations in HDAC expression in malaria parasites may be
associated with reduced clinical artemisinin efficacy (45), rais-
ing the possibility that HDAC inhibitors might contribute to
future drug combinations aimed at addressing the issue of ar-
temisinin resistance. Such findings underscore the potential for
HDAC inhibitors to be used for malaria therapy. However, to
progress HDAC inhibitors toward clinical trials for malaria,
next-generation compounds must have potent antiplasmodial
activity, highly selective killing action against parasites rather
than normal host cells, and improved bioavailability and phar-
macokinetic profiles after oral dosing. In this study, we dem-
onstrated that SB939, a new orally bioavailable HDAC inhibi-
tor with a superior pharmacokinetic profile over those of
previous HDAC inhibitors such as SAHA, has potent activity
against asexual- and sporozoite-stage Plasmodium parasites
and promising in vivo activity in a mouse model of malaria
infection. These findings support the development of HDAC
inhibitors as a potential new antimalarial compound class.
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